RBC Capital Cuts Price Target on CVS Health (NYSE:CVS) to $91 From $102, Maintains Outperform Rating.
RBC Capital Cuts Price Target on CVS Health (NYSE:CVS) to $91 From $102 Read Post »
CVS Health (NYSE:CVS) Affirms 2023 Adjusted EPS Outlook $8.50-$8.70.
CVS Health (NYSE:CVS) Affirms 2023 Adjusted EPS Outlook $8.50-$8.70 Read Post »
Bernstein analyst William Pickering maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $380 to $390.
Bernstein raises Vertex Pharmaceuticals (NASDAQ:VRTX) price target from $380 to $390 Read Post »
Vertex (NASDAQ:VRTX) Raises Full Year 2023 Product Revenue Guidance From $9.55B-$9.7B To $9.7B-$9.8B.
Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 adjusted net income of $3.89 per diluted share, up from $3.60 a year earlier. Analysts polled by Capital IQ expected $3.88. Revenue for the quarter ended June 30 was $2.49 billion, up from $2.2 billion a year earlier. Analysts surveyed by Capital IQ forecast $2.42 billion. The biotech firm said it now expects fiscal 2023 revenue of $9.7 billion to $9.8 billion, up from $9.55 billion to $9.7 billion previously. Analysts polled by Capital IQ are looking for $9.75 billion.
JPMorgan Adjusts Price Target on Pfizer (NYSE:PFE) to $39 From $41, Maintains Neutral Rating.
JPMorgan Adjusts Price Target on Pfizer (NYSE:PFE) to $39 From $41 Read Post »
Merck (NYSE:MRK) reported a Q2 non-GAAP loss of $2.06 per share, down from EPS of $1.87 a year ago. Analysts polled by Capital IQ expected a loss of $2.18. Sales for the quarter ended June 30 were $15.04 billion, up from $14.59 billion a year earlier. Analysts surveyed by Capital IQ expected $14.44 billion. The company said it now expects 2023 non-GAAP EPS of $2.95 to $3.05, compared with the prior estimate of $6.88 to $7. Analysts surveyed by Capital IQ expect $2.92. The company now expects 2023 sales to be between $58.6 billion to $59.6 billion, compared with the previous projection of $57.7 billion to $58.9 billion. Analysts polled by Capital IQ expect $58.65 billion.
Merck (NYSE:MRK) Swings to Q2 Loss; Raises Guidance Range for 2023 Revenue Read Post »
Pfizer (NYSE:PFE) Revises FY23 Revenue Guidance To $67B-$70B Vs. Consensus Of $61.01B And Prior Guidance Of $67B-$71B; Adjusts 2023 Non-COVID Operational Revenue Growth Expectation to 6%-8%.
Pfizer (NYSE:PFE) FY23 Revenue Guidance To $67B-$70B Vs. Consensus Of $61.01B Read Post »
Pfizer (NYSE:PFE) Q2 Revenue $12.734 Bln Vs. $27.742 Bln a Year Ago; FactSet Consensus $13.363 Bln。
Pfizer (NYSE:PFE) Q2 Revenue $12.734 Bln Vs. FactSet Consensus $13.363 Bln Read Post »
Barclays analyst Matt Miksic maintains Boston Scientific (NYSE:BSX) with a Overweight and raises the price target from $56 to $59.
Barclays raises Boston Scientific (NYSE:BSX) price target from $56 to $59 Read Post »
Centene (NYSE:CNC) reported Q2 adjusted earnings Friday of $2.10 per diluted share, up from $1.77 per share a year earlier. Analysts polled by Capital IQ estimated adjusted EPS of $2.05. Revenue for the quarter ended June 30 was $37.61 billion, compared with $35.94 billion a year earlier. Analysts surveyed by Capital IQ expected $36.54 billion. The company said it expects 2023 adjusted EPS of at least $6.45, up from the previous outlook of $6.40. Analysts polled by Capital IQ expect adjusted EPS of $6.47. Revenue for the year is projected to be $147.3 billion to $149.3 billion, compared with the prior guidance of $144.5 billion to $146.5 billion. Analysts polled by Capital IQ expect $146.43 billion.
Centene (NYSE:CNC) Q2 Adjusted Earnings, Revenue Increase; Updates 2023 Outlook Read Post »
Barclays analyst Steve Valiquette maintains Centene (NYSE:CNC) with a Overweight and lowers the price target from $86 to $85.
Barclays lowers Centene (NYSE:CNC) price target from $86 to $85 Read Post »